TSHA-120 is under clinical development by Astellas Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect TSHA-120’s likelihood of approval (LoA) and phase transition for Neuropathy took place on 27 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TSHA-120 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

TSHA-120 overview

TSHA-120 is under development for the treatment of giant axonal neuropathy. It is administered via intrathecal route. The drug candidate is a self-complementary adeno-associated virus serotype 9 vector (AAV9) carrying a codon-optimized human GAN transgene controlled by the minimal synthetic JeT promoter. The therapy targets and replaces the lost function of gigaxonin gene.

Astellas Pharma overview

Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

Quick View TSHA-120 LOA Data

Report Segments
  • Innovator
Drug Name
  • TSHA-120
Administration Pathway
  • Intrathecal
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: Astellas Pharma
  • Originator: University of North Carolina at Chapel Hill
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.